2019 logo_150x35_jpg.jpg
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
June 10, 2021 08:30 ET | Novan, Inc.
– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...
2019 logo_150x35_jpg.jpg
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:05 ET | Novan, Inc.
– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating...